154 related articles for article (PubMed ID: 38172984)
1. Histone acetylation: a key determinant of acquired cisplatin resistance in cancer.
Natu A; Verma T; Khade B; Thorat R; Gera P; Dhara S; Gupta S
Clin Epigenetics; 2024 Jan; 16(1):8. PubMed ID: 38172984
[TBL] [Abstract][Full Text] [Related]
2. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of PI3K/AKT in tumor-related epigenetic regulation.
Yang Q; Jiang W; Hou P
Semin Cancer Biol; 2019 Dec; 59():112-124. PubMed ID: 30951826
[TBL] [Abstract][Full Text] [Related]
5. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract][Full Text] [Related]
6. HDAC3-mediated lncRNA-LOC101928316 contributes to cisplatin resistance in gastric cancer via activating the PI3K-Akt-mTOR pathway.
Ren H; Tang L
Neoplasma; 2021 Sep; 68(5):1043-1051. PubMed ID: 34427099
[TBL] [Abstract][Full Text] [Related]
7. An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.
Wu D; Yan Y; Wei T; Ye Z; Xiao Y; Pan Y; Orme JJ; Wang D; Wang L; Ren S; Huang H
Cell Rep; 2021 Feb; 34(7):108744. PubMed ID: 33596421
[TBL] [Abstract][Full Text] [Related]
8. PSAT1 Upregulation Contributes to Cell Growth and Cisplatin Resistance in Cervical Cancer Cells via Regulating PI3K/AKT Signaling Pathway.
Duan W; Liu X
Ann Clin Lab Sci; 2020 Jul; 50(4):512-518. PubMed ID: 32826249
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
[TBL] [Abstract][Full Text] [Related]
10. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
11. Suppression of the Antioxidant System and PI3K/Akt/mTOR Signaling Pathway in Cisplatin-Resistant Cancer Cells by Quercetin.
Hasan AAS; Kalinina EV; Tatarskiy VV; Volodina YL; Petrova АS; Novichkova MD; Zhdanov DD; Shtil AA
Bull Exp Biol Med; 2022 Oct; 173(6):760-764. PubMed ID: 36322312
[TBL] [Abstract][Full Text] [Related]
12. Investigation on the mechanism of the combination of eremias multiocellata and cisplatin in reducing chemoresistance of gastric cancer based on
Cheng FE; Li Z; Bai X; Jing Y; Zhang J; Shi X; Li T; Li W
Aging (Albany NY); 2024 Feb; 16(4):3386-3403. PubMed ID: 38345573
[TBL] [Abstract][Full Text] [Related]
13. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
14. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
15. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Yin S; Mai Z; Liu C; Xu L; Xia C
Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of microarray data to determine gene indicators involved in the cisplatin resistance in ovarian cancer.
Hashemi Sheikhshabani S; Amini-Farsani Z; Kazemifard N; Modarres P; Amini-Farsani Z; Omrani MD; Ghafouri-Fard S
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1884. PubMed ID: 37937323
[TBL] [Abstract][Full Text] [Related]
17. H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor.
Kohli A; Huang SL; Chang TC; Chao CC; Sun NK
Cancer Sci; 2022 Aug; 113(8):2616-2626. PubMed ID: 35639349
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
20. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]